Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Shares Issued (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Shares Issued data on record, last reported at $38.4 million in Q4 2023.

  • For Q4 2023, Shares Issued rose 3229.4% year-over-year to $38.4 million; the TTM value through Dec 2023 reached $38.4 million, up 3229.4%, while the annual FY2024 figure was $262.7 million, 584.2% up from the prior year.
  • Shares Issued reached $38.4 million in Q4 2023 per CGEM's latest filing, up from $1.2 million in the prior quarter.
  • Across five years, Shares Issued topped out at $267.3 million in Q1 2021 and bottomed at -$267.3 million in Q2 2021.
  • Average Shares Issued over 4 years is $5.8 million, with a median of $1.2 million recorded in 2022.
  • Peak YoY movement for Shares Issued: plummeted 33098.38% in 2021, then soared 3229.4% in 2023.
  • A 4-year view of Shares Issued shows it stood at $800000.0 in 2020, then tumbled by 33098.38% to -$264.0 million in 2021, then surged by 100.44% to $1.2 million in 2022, then skyrocketed by 3229.4% to $38.4 million in 2023.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $38.4 million in Q4 2023, $1.2 million in Q4 2022, and -$1.2 million in Q2 2022.